HIV-1 integration is inhibited by stimulation of the VPAC2 neuroendocrine receptor

Virology

Volumn 362, Issue 1, 2007, Pages 38-49

  Bokaei, Payman Baradar ^a,c   Ma, Xue Zhong ^a   Sakac, Darinka ^c   Branch, Donald R ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c DEFENCE RESEARCH AND DEVELOPMENT CANADA   (Canada)

Author keywords

Helodermin; HIV integration; HIV AIDS; VPAC2 agonists; VPAC2 receptor

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; CD4 ANTIGEN; COMPLEMENTARY DNA; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2 AFFECTING AGENT; VIRUS RNA;

APOPTOSIS; ARTICLE; CELL SURFACE; CONTROLLED STUDY; DRUG INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REPORTER GENE; REVERSE TRANSCRIPTION; VIRUS DNA CELL DNA INTERACTION; VIRUS TRANSCRIPTION;

APOPTOSIS; CELL LINE; CELLS, CULTURED; GENES, REPORTER; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; JURKAT CELLS; LEUKOCYTES, MONONUCLEAR; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE, TYPE I; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; REVERSE TRANSCRIPTION; VIRUS INTEGRATION; VIRUS INTERNALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34247201596     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2006.12.012     Document Type: Article

References (49)

1. Alkhatib G., Combadiere C., Broder C.C., Feng Y., Kennedy P.E., Murphy P.M., and Berger E.A. CC CKR5: a RANTES, MIP-1alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272 5270 (1996) 1955-1958
2. Arimura A., and Shioda S. Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors: neuroendocrine and endocrine interaction. Front. Neuroendocrinol. 16 1 (1995) 53-88
3. Baiocchi M., Olivetta E., Chelucci C., Santarcangelo A.C., Bona R., d'Aloja P., Testa U., Komatsu N., Verani P., and Federico M. Human immunodeficiency virus (HIV)-resistant CD4+ UT-7 megakaryocytic human cell line becomes highly HIV-1 and HIV-2 susceptible upon CXCR4 transfection: induction of cell differentiation by HIV-1 infection. Blood 89 8 (1997) 2670-2678
4. Bokaei P.B., Ma X.-Z., Byczynski B., Keller J., Sakac D., Fahim S., and Branch D.R. Identification and characterization of 5-transmembrane isoforms of human vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide receptors. Genomics 88 6 (2006) 791-800
5. Bouchonnet F., Dam E., Mammano F., de Soultrait V., Hennere G., Benech H., Clavel F., and Hance A.J. Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conffering human immunodeficiency virus type 1 resistance to nucleoside analogues. J. Virol. 79 2 (2005) 812-822
6. Branch D.R., Valenta L.J., Yousefi S., Sakac D., Singla R., Bali M., Sahai B.M., and Ma X.Z. VPAC1 is a cellular neuroendocrine receptor expressed on T cells that actively facilitates productive HIV-1 infection. AIDS 16 3 (2002) 309-319
7. Chang L.J., Urlacher V., Iwakuma T., Cui Y., and Zucali J. Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system. Gene Ther. 6 5 (1999) 715-728
8. Connor R.I., Chen B.K., Choe S., and Landau N.R. Vpr is required for efficient replication of immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206 2 (1995) 935-944
9. Dalgleish A.G., Beverley P.C., Clapham P.R., Crawford D.H., Greaves M.F., and Weiss R.A. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312 5996 (1984) 763-767
10. Daniel R., Kao G., Taganov K., Greger J.G., Favorova O., Merkel G., Yen T.J., Katz R.A., and Skalka A.M. Evidence that the retroviral DNA integration process triggers an ATR-dependent DNA damage response. Proc. Natl. Acad. Sci. U.S.A. 100 8 (2003) 4778-4783
11. Dupre J. Glycaemic effects of incretins in Type I diabetes mellitus: a concise review with emphasis on studies in humans. Regul. Pept. 128 2 (2005) 149-157
12. Fantini J., Hammache D., Pieroni G., and Yahi N. Role of glycosphingolipid microdomains in CD4-dependent HIV-1 fusion. Glycoconj. J. 17 3-4 (2000) 199-204
13. Feng Y., Broder C.C., Kennedy P.E., and Berger E.A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane G protein-coupled receptor. Science 272 5263 (1996) 872-877
14. Gibellini D., Vitone F., Schiavone P., Ponti C., La Placa M., and Re M.C. Quantitative detection of human immunodeficiency virus type 1 (HIV-1) proviral DNA in peripheral blood mononuclear cells by SYBR green real-time PCR technique. J. Clin. Virol. 29 4 (2004) 282-289
15. Gilles A., Miquelis A., Luis J., and Faure E. Activation of transcription from the human immunodeficiency virus type 1 (HIV-1) long terminal repeat by the vasoactive intestinal peptide (VIP). Ital. J. Biochem. 47 2 (1998) 101-110
16. Gourlet P., Vandermeers A., Vertongen P., Rathe J., De Neef P., Cnudde J., Waelbroeck M., and Robberecht P. Development of high affinity selective VIP1 receptor agonists. Peptides 18 10 (1997) 1539-1545
17. Gourlet P., Vertongen P., Vandermeers A., Vandermeers-Piret M.C., Rathe J., De Neef P., Waelbroeck M., and Robberecht P. The long-acting vasoactive intestinal polypeptide agonist RO25-1553 is highly selective of the VIP2 receptor subclass. Peptides 18 3 (1997) 403-408
18. Harmar A.J., Arimura A., Gozes I., Journot L., Laburthe M., Pisegna J.R., Rawlings S.R., Robberecht P., Said S.I., Sreedharan S.P., Wank S.A., and Waschek J. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol. Rev. 50 2 (1998) 265-270
19. Hirsh L., Ben-Ami I., Freimann S., Dantes A., Tajima K., Kotsuji F., and Amsterdam A. Desensitization to gonadotropic hormones: a model system for the regulation of a G-protein-coupled receptor with 7-transmembrane spanning regions. Biochem. Biophys. Res. Commun. 326 1 (2005) 1-6
20. Hong C., Voralia M., Bali M., Sher G.D., and Branch D.R. Irreversible loss of donor blood leucocyte activation may explain a paucity of transfusion-associated graft-versus-host disease from stored blood. Br. J. Haematol. 111 1 (2000) 146-156
21. Kurmayer R., and Kutzenberger T. Application of real-time PCR for quantification of microcystin genotypes in a population of the toxic cyanobacterium Microcystis. Appl. Environ. Microbiol. 69 11 (2003) 6723-6730
22. Langer I., Gregoire F., Nachtergael I., De Neef P., Vertongen P., and Robberecht P. Hexanoylation of a VPAC2 receptor- preferring ligand markedly increased its selectivity and potency. Peptides 25 2 (2004) 275-278
23. Langlet C., Gaspard N., Nachtergael I., Robberecht P., and Langer I. Comparative efficacy of VIP and analogs on activation and internalization of the recombinant VPAC2 receptor expressed in CHO cells. Peptides 25 12 (2004) 2079-2086
24. Lara-Marquez M., O'Dorisio M., O'Dorisio T., Shah M., and Karacay B. Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells. J. Immunol. 166 4 (2001) 2522-2530
25. Lund N., Branch D.R., Mylvaganam M., Chark D., Ma X.Z., Sakac D., Binnington B., Fantini J., Puri A., Blumenthal R., and Lingwood C.A. A novel soluble mimic of the glycolipid, globotriaosyl ceramide inhibits HIV infection. AIDS 20 3 (2006) 333-343
26. Mercure L., Brenner B.J., Phaneuf D., Tsoukas C., and Wainberg M.A. Effect of 3′-azido-3′-deoxythymidine and 2′,3′-didioxyinosine on establishment of human immunodeficiency virus type 1 in cultured CD8+ lymphocytes. Anthimicrob. Agents Chemother. 38 5 (1994) 986-990
27. Nicole P., Du K., Couvineau A., and Laburthe M. Site-directed mutagenesis of human vasoactive intestinal peptide receptor subtypes VIP1 and VIP2: evidence for difference in the structure-function relationship. J. Pharmacol. Exp. Ther. 284 2 (1998) 744-750
28. Perry, T.A., Greig, N.H., 2004. A new Alzheimer's disease interventive strategy: GLP-1 Curr. Drug Targets 5 (6), 565-571.
29. Pert C.B., Ruff M.R., and Hill J.M. AIDS as a neuropeptide disorder: peptide T, VIP, and the HIV receptor. Psychopharmacol. Bull. 24 3 (1988) 315-319
30. Pohl M., and Wank SA. Molecular cloning of the helodermin and exendin-4 cDNAs in the lizard. Relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian homologues. J. Biol. Chem. 273 16 (1998) 9778-9784
31. Puri A., Rawat S.S., Lin H.M., Finnegan C.M., Mikovits J., Ruscetti F.W., and Blumenthal R. An inhibitor of glycosphingolipid metabolism blocks HIV-1 infection of primary T-cells. AIDS 18 6 (2004) 849-858
32. Robberecht P., Gourlet P., Vertongen P., and Svoboda M. Characterization of the VIP receptor from SUP T1 lymphoblasts. Adv. Neurobionol. 6 1 (1996) 49-57
33. Sausville E.A., Elsayed Y., Monga M., and Kim G. Signal transduction-directed cancer treatments. Ann. Rev. Pharmacol. Toxicol. 43 (2003) 199-231
34. Schulz S., Rocken C., Mawrin C., Weise W., Hollt V., and Schulz S. Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies. Clin. Cancer Res. 10 24 (2004) 8235-8242
35. Serafini M., Naldini L., and Introna M. Molecular evidence of inefficient transduction of proliferating human B lymphocytes by VSV-pseudotyrped HIV-1-derived lentivectors. Virology 325 2 (2004) 413-424
36. Sreedharan S.P., Patel D.R., Huang J.X., and Goetzl E.J. Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor. Biochem. Biophys. Res. Commun. 193 2 (1993) 546-553
37. Svoboda M., Tastenoy M., Van Rampelbergh J., Goossens J.F., De Neef P., Waelbroeck M., and Robberecht P. Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts. Biochem. Biophys. Res. Commun. 205 3 (1994) 1617-1624
38. Taddeo B., Federico M., Titti F., Rossi G.B., and Verani P. Homologous superinfection of both producer and nonproducer HIV-infected cells is blocked at a late retrotranscription step. Virology 194 2 (1993) 441-452
39. Tsutsumi M., Claus T.H., Liang Y., Li Y., Yang L., Zhu J., Dela Cruz F., Peng X., Chen H., Yung S.L., Hamren S., Livingston J.N., and Pan C.Q. A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes. Diabetes 51 5 (2002) 1453-1460
40. Turville S., Wilkinson J., Cameron P., Dable J., and Cunningham A.L. The role of dendritic cell C-type lectin receptors in HIV pathogenesis. J. Leukoc. Biol. 74 5 (2003) 710-718
41. Ulrich C.D., Holtmann M., and Miller L.J. Secretin and vasoactive intestinal peptide receptors: members of a unique family of G protein-coupled receptors. Gastroenterology 114 2 (1998) 382-397
42. Usdin T.B., Bonner T.I., and Mezey E. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 135 6 (1994) 2662-2680
43. Veljkovic V., Metlas R., Raspopovic J., and Pongor S. Spectral and sequence similarity between vasoactive intestinal peptide and the second conserved region of human immunodeficiency virus type 1 envelope glycoprotein (gp120): possible consequences on prevention and therapy of AIDS. Biochem. Biophys. Res. Commun. 189 2 (1992) 705-710
44. Vey N., Bosly A., Guerci A., Feremans W., Dombret H., Dreyfus F., Bowen D., Burnett A., Dennis M., Ribrag V., Casadevall N., Legros L., and Fenaux P. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. J. Clin. Oncol. 24 16 (2006) 2465-2471
45. Victoria J.G., Lee D.J., McDougall B.R., and Robinson Jr. W.E. Replication kinetics for divergent type 1 human immunodeficiency viruses using quantitative SYBR green I real-time polymerase chain reaction. AIDS Res. Hum. Retroviruses 19 10 (2003) 865-874
46. Vitone F., Gibellini D., Schiavone P., Ponti C., La Placa M., and Re M.C. Quantitative DNA proviral detection in HIV-1 patients treated with antiretroviral therapy. J. Clin. Virol. 33 3 (2005) 194-200
47. Xia M., Gaufo G.O., Wang Q., Sreedharan S.P., and Goetzl E.J. Transduction of specific inhibition of HuT 78 human T cell chemotaxis by type I vasoactive intestinal peptide receptors. J. Immunol. 157 3 (1996) 1132-1138
48. Yung S.L., Dela Cruz F., Hamren S., Zhu J., Tsutsumi M., Bloom J.W., Caudle M., Roczniak S., Todd T., Lemoine L., MacDougall M., Shanafelt A.B., and Pan C.Q. Generation of highly selective VPAC2 receptor agonists by high throughput mutagenesis of vasoactive intestinal peptide and pituitary adenylate cyclase- activating peptide. J. Biol. Chem. 278 12 (2003) 10273-10281
49. Zack J.A., Arrigo S.J., Weitsman S.R., Go A.S., Haislip A., and Chen I.S. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61 2 (1990) 213-222